Literature DB >> 6420458

Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

F Iannotta, P Fachinetti, A Fachinetti, G Pinotti, L Usellini.   

Abstract

Nomifensine, TRH and insulin-induced hypoglycemia tests were carried out in 37 cases of hyperprolactinemia: 25 were due to PRL-secreting pituitary tumors, 6 cases to GH and PRL-secreting pituitary tumors and 6 to pituitary and suprasellar non secreting tumors. Nomifensine failed to suppress the serum PRL in all subjects and PRL responses to TRH and insulin-induced hypoglycemia were impaired in all patients, irrespective of the origin of hyperprolactinemia. The uniform pattern of PRL response to the above tests in patients with hyperprolactinemia of variable etiology suggests that none of them is specific for prolactinomas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6420458     DOI: 10.1007/BF03347615

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

Review 1.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

2.  A new pharmacological approach to the diagnosis of hyperprolactinaemic states: the nomifensine test.

Authors:  A R Genazzani; F Camanni; F Massara; E Picciolini; D Cocchi; L Belforte; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1980-02

3.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

4.  Ultrastructural classification of pituitary adenomas.

Authors:  E Horvath; K Kovacs
Journal:  Can J Neurol Sci       Date:  1976-02       Impact factor: 2.104

5.  Argyrophil pituitary tumors showing TSH cells or small granule cells.

Authors:  C Capella; L Usellini; B Frigerio; R Buffa; P Fontana; E Solcia
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-03-23

6.  Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.

Authors:  K Kamoi; I Tchuchida; H Sato; R Tanaka; T Ishiguro; K Kaneko; Y Iwasaki; A Shibata
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

7.  Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation.

Authors:  M E Quigley; S J Judd; G B Gilliland; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

8.  Tests of prolactin secretion in diagnosis of prolactinomas.

Authors:  E A Cowden; J G Ratcliffe; J A Thomson; P Macpherson; D Doyle; G M Teasdale
Journal:  Lancet       Date:  1979-06-02       Impact factor: 79.321

9.  Nomifensine: diagnostic test in hyperprolactinemic states.

Authors:  E E Müller; A R Genazzani; S Murru
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

10.  Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.

Authors:  P Moriondo; P Travaglini; M Nissim; G Faglia
Journal:  Clin Endocrinol (Oxf)       Date:  1980-12       Impact factor: 3.478

View more
  3 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Nomifensine in hyperprolactinemic states.

Authors:  E E Müller; F Camanni; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

3.  More on nomifensine.

Authors:  A Liuzzi; P G Chiodini
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.